Lekkas, Dr Anastasios
Respiratory and general medicine
- critical care (respiratory high dependency unit)
- lung cancer
- non-intensive ventilation in neuromuscular disorders and chronic decompensated lung disease
- bronchoscopy (diagnostic and interventional)
Training and education
- MSc in respiratory medicine, UCL-Imperial College, London 2004.
- CCT in intensive care, London Deanery, 2007.
- CCT in respiratory medicine and general medicine, North West Thames, London Deanery, 2007.
- FRCP Royal College of Physicians, London 2012.
Dr Lekkas is a consultant respiratory physician who's worked for the Trust since September 2007. He runs our lung cancer clinic (he's chair of the lung cancer focus group), pulmonary nodule clinic and non-invasive ventilation clinic.
Dr Lekkas undertook specialist training in respiratory and general medicine in North West Thames London Deanery, rotating through the following hospitals: Imperial Hospital NHS Trust, Royal Brompton Hospital NHS Trust, Harefield Hospital, St George’s Healthcare NHS Trust, The Royal Sussex County Hospital, Ealing Hospital NHS Trust and Charing Cross Hospital NHS. He was also trained in intensive care medicine at London Deanery.
Dr Lekkas is a core member of the following committees:
- chair of the Medicine Evaluation Committee, Hampshire
- chair of the lung cancer focus group, University Hospital of Southampton Foundation NHS Trust
- member of the District Prescribing Committee, Hampshire
- member of the Southampton Prescribing Committee
Dr Lekkas is also an advisor for the British National Formulary and NICE appraisals regarding respiratory medicines.
Dr Lekkas is currently a chief investigator in a study to understand more about how the immune system works in lung disease (TargetLung). The information from this study will help us better understand how the immune system works when people have lung cancer and other lung diseases. It will also help us to understand the immune system in relation to lung cancer and other lung conditions. Dr Lekkas hope that the results will guide us to developing better treatments for lung cancer. Supporters of this study include: Experimental Cancer Medicine Centre (ECMC), NIHR Clinical Research Network: Cancer and University Hospital Southampton NHS Foundation Trust.